Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Seuss who wrote (883)	7/13/1999 4:35:00 PM
From: cirrus	Read Replies (1) \| Respond to of 2515

When products come to market the rate of price appreciation may well slow as IMCL will be valued like other companies - stuff like PE ratios, quarterly earnings, competitors products and the like will become more important. However, IMCL may well be trading at $150 then. Now is the golden age - a pure play on a future that appears extraordinarily promising. Enjoy the ride and hope the trials do not disclose anything that might cause the FDA to delay approval. >>>anyone care to venture what will happen if/when these drugs come on line?<<<

To: Dr. Seuss who wrote (883)	7/13/1999 5:58:00 PM
From: Edscharp	Read Replies (4) \| Respond to of 2515

Seuss, I am familiar with your handle. You and Auric do seem to have a talent for inciting the longs (especially Auric). In any event, welcome to Imclone. I've mostly just lurked here myself. I am a bit surprised to see a dedicated shorter investing in Imclone. Honestly, Imclone is a crap shoot. Everything pretty much depends on C225 doing well in P3 trials, then getting final approval by the FDA. P2 trials were impressive, but that's not a guarantee. It'll be a long wait, but worth it if C225 "works".